Recently, EasyDiagnosis disclosed its third quarterly report, the company achieved revenue of 7.47 billion CNY in the first three quarters, an increase of 285.38% year-on-year; achieved net profit of 3.838 billion CNY, an increase of 281.76% year-on-year. Among them, the company achieved revenue of 2.217 billion CNY in the third quarter, an increase of 178.14% year-on-year, and net profit of 1.078 billion CNY, an increase of 153.12% year-on-year.

Innovation is the inexhaustible power of enterprise development. Since its establishment, EasyDiagnosis has always attached great importance to the R&D innovation of high technology. The R&D expenses in the first three quarters of this year reached 155 million CNY, compared with 78.72 million CNY in the same period of the previous year, an increase of 97.29% year-on-year, more than last year's full-year R&D expenses.

It is worth noting that in the first half of this year, EasyDiagnosis 's R&D expenses were only 56.9052 million CNY. This means that in the third quarter alone, EasyDiagnosis invested 98.4057 million CNY in R&D expenses, compared to only 29.4906 million CNY in the same period of the previous year. Since the listing of EasyDiagnosis in July 2018, the company's R&D expenses from 2018 to 2021 are 27.1 million CNY, 36.96 million CNY, 69.93 million CNY and 132.7 million CNY, respectively, with R&D expenses starting almost exponentially since 2020.

In the third quarter of this year, EasyDiagnosis announced its intention to increase capital by 10 million CNY to subscribe to the additional registered capital of 150,000 CNY of DigiFluidic, and after this transaction, the company will hold 4.0032% of the latter's equity.

About EasyDiagnosis:

Wuhan EasyDiagnosis Biomedicine Co., Ltd was established in Wuhan Optics Valley in 2008 and went public in 2018 (Shenzhen Stock Exchange code 002932), EasyDiagnosis is a Chinese national high-tech enterprise specializing in R&D, production and sales of In-Vitro Diagnostics reagents and auxiliary equipment in fields of POCT, chemiluminescence, blood gas analysis, molecular diagnosis, etc.

We were the first company in China to make bedside, rapid quantitative detection in whole blood, and now we have a strong and professional R&D team, with class 100,000 cleanroom workshop and international leading production lines. Our POCT products cover fields of cardiovascular disease, kidney disease, infectious disease, endocrine and metabolic diseases, obstetrics, gynecology disease and physical examination. EasyDiagnosis have been certified with ISO13485：2016, so far we have more than 100 products certified with NMPA and 8 products with CE certification, we have 68 authorized patents, in the meantime, our sales network has reached about 100 countries and regions across the world.